OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-06-30-accounts

COMPANY REGISTRATION NUMBER : 7225131

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE UNAUDITED FINANCIAL STATEMENTS FOR YEAR ENDED 30 JUNE 2021

Charity Number : 1136067

Edmund Carr LLP Chartered Accountants 146 New London Road

Chelmsford Essex CM2 OAW

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

CONTENTS PAGE
Company information 1
Trustees' annual report 2
Independent Examiner's report to the Trustees 10
Statement of financial activities 11
Balance sheet 12
Notes to the financial statements 13

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

COMPANY INFORMATION

YEAR ENDED 30 JUNE 2021

Charity Number 1136067 Company Number 7225131 Registered Office 35-43 Lincoln's Inn Fields London WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Mr Hassan Malik President Mr Zaed Hamady Vice President Mr John Whiting Honorary Treasurer Mr Michael Shackcloth EJSO Representative Professor Michael Douek Honorary Secretary Professor Jim Khan Meeting Secretary Professor Jayant Vaidya Deputy Meeting Secretary Mr Edmund Leung Professor Derek Manas Professor Richard Shaw Mr Aaron Quyn (Appointed 23/11/2020) Mr Anant Desai (Appointed 23/11/2020) Mr Riccardo Bonomi (Resigned 23/11/2020)

-1-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE TRUSTEES' ANNUAL REPORT

YEAR ENDED 30 JUNE 2021

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the period ended 30th June 2021. The Trustees of the charity as shown on page 1 are also the directors of the charity.

Objectives and Activities

The Charity’s objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and to promote research, training, and education in surgical oncology for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association seeks to act as an umbrella organisation for those working in all surgical cancer specialties and cancer research. In addition, the Society focuses on innovation in cancer care and support for future workforce training and development. The Trustees pay due regard to the Charity Commission’s guidance on public benefit when deciding what activities the Charity should undertake.

Portfolio of Awards

The Association takes great pride in its portfolio of awards to encourage our junior colleagues and to support their interest in the field of surgical oncology, its research and care of cancer patients. The Society continues awarding the following prizes at its annual scientific meeting:

To expand its commitment to all cancer-related professionals, BASO announced the following two new prizes at the 2019 BASO Annual Scientific Meeting:

BASO Grants

BASO is expanding its portfolio of research grants to support cancer research and treatment.

BASO Raven Travelling Fellowship - (formerly known as Ronald Raven Travelling Fellowship) was endowed in 1993 by the Ronald Raven Trustees in memory of the Founder of the Association’s Ronald W. Raven. BASO Continues to fund and award this fellowship, which has now increased to £3,000, each year to aspiring trainees to support them to expand their skills and experience in the surgical cancer treatment.

-2-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

BASO (NIHR) Research Project Grant - BASO continues to be a non-commercial partner with the National Institute of Health Research (NIHR) and runs a successful annual research project grant scheme to assist surgeons in undertaking research projects related to surgically linked cancer care. This grant is open for discrete projects and a study awarded this grant is automatically eligible for consideration for the Clinical Research Network Support, thereby, is considered for being a portfolio study.

Endorsement of Regional Events

The Association aspires to engage with oncologists and Societies on the regional level. Via its network of Regional Representatives, BASO had been supporting various regional and national meetings. However, the participation has been limited during this accounting year due to the COVID.

Engagement with Medical Students

In the spirit of encouraging the future generation of surgical oncologists, the Association has opened its Trainees membership to Foundation Year Trainees and Medical Students those wishing to pursue surgical oncology. BASO aims to offer support with their surgical career by providing skills courses, mentoring sessions, and guiding surgical portfolio via our wealth of regional representatives.

The Society is actively engaging with undergraduate Medical Societies by sponsoring their annual meeting with BASO Prize and sponsored lectures.

BASO Trainees Group

BASO Trainees group continued growing their outlook and strengthened their links with trainees groups from across Europe. Through these collaborations, we encouraged trainees in tenets of research and clinical excellence in surgical oncology through the sponsored prizes at national specialty meetings. Our Trainees group continues to focus on research, academic training, and fellowships.

BASO @ the ACCEA Committee

In addition to its role within education and training, BASO is one of the selected few organisations that play a significant role in the assessment of and nominations for the Clinical Excellence Awards. BASO Council continues to sit on the ACCEA Award Committee and offers consultation to the ACCEA Focus Group.

BASO’s contribution to NICE consultations and Cancer CRGs

The Society continues to make its mark and offers expert advice on numerous site-specific Surgical Cancer consultations as requested by NICE. Our Council members sit on various Cancer CRG’s, offering expert advice.

Overall, the Society is maintaining healthy relations with all the surgical societies, the Royal Colleges, and exploring collaborative working opportunities.

Achievements and Performance

The Society has been proactive in dealing with the COVID-19 pandemic and its challenges have demonstrated the need for an umbrella organisation to speak with one voice. BASO is growing its membership, maintained steady finances and delivered a successful virtual meetings this year.

COVID –19

BASO is actively engaged in supporting our members and front-line clinicians to continue providing essential cancer surgery. BASO had issued the ‘Strategy for Cancer Surgery sustainability and recovery in the COVID19 pandemic’ guidance to support its members.

-3-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

An edited version of BASO's guidance was produced as a joint letter on behalf of ESSO and BASO to the Editor of the EJSO with a vision to expand our message to our colleagues in other European Countries. BASO’s guidance was well received by our members and fellow colleagues, and was supported by numerous national and international surgical societies.

BASO also contributed to the NHS England document, 'Maintenance of Essential Cancer surgery for adults during the COVID-19 emergency'. BASO’s recommendations, particularly, on screening, self-isolation of patients, and shielding of patients were included in the NHSE document.

BASO is also actively engaged with the CovidSurg-Cancer Study and is one of the key sponsors of this study. CovidSurg-Cancer is an international cohort study, designed by the team in Birmingham to assess the safety of surgery for all types of cancer during COVID-19 pandemic and the impact of pandemic in cancer delay and treatment pathways. BASO, as the non-commercial NIHR partner, is one of the Societies that offers a small surgical research grant to this study which would entitle it to be listed on the NIHR Portfolio.

The COVID-19 Pandemic has put immense strain on our healthcare system, however, our Trustees also believe that it has also led to innovation in a short period of time, and hope to continue providing support to our members and cancer community.

BASO Annual Meeting

2020 had been a challenging year and to support the ongoing education needs of its members and surgical community during these difficult times, BASO delivered its first virtual Annual Meeting. The meeting was themed on Education” and was delivered under the leadership of our President Mr Hassan Malik and Professor Michael Douek as the Meeting Secretary.

The meeting was facilitated by an array of international speakers and panellists, all esteemed surgeons in the field of surgical oncology and had an attendance of 170 delegates. The feedback received from delegates and speakers was extremely positive, both about the content of the programme and the virtual organisation. The meeting generated a small profit.

94 abstracts were presented under oral or poster presentation sessions, and 8 prizes were awarded for best abstract presentations. It was however decided by the BASO Council to postpone the prestigious BASO Plenary Awards until 2021, to ensure that these awards were presented in person.

The key highlights of the programme were:

The Association aspires to continue building on the success of this programme and making BASO meetings financially sustainable.

-4-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

European Journal of Surgical Oncology

The EJSO , co-owned by BASO and the ESSO continues to go from strength to strength with a rise in the quality of submission and article downloads. The 2020 impact factor were released earlier in June. The EJSO impact factor has increased to 4.424 from 3.959 from last year. (Follow link for more details: - https://journalinsights.elsevier.com/journals/0748 7983/impact_factor). This is a remarkable jump in citations and credit must be given to the editorial team led by our past President Professor Riccardo Audisio (Editor in Chief).

Network and links with other organisations

The Association continues to grow its links with other specialties and to re-establish itself as the umbrella organisation for cancer surgeons, including forming membership links with other specialties and setting up partnerships for joint conferences in future.

Our BASO Trainees Group is also proactively expanding its partnership opportunities and has representation on the ASiT Council. BASO Trainees maintains a portfolio of Trainees Prizes of £100 each for the best surgical oncology presentations at the Annual ASiT Conference, and SCTS Annual Meeting held this year.

European Society of Surgical Oncology

BASO had signed a ’memorandum-of-understanding’ with our European sister society ESSO to strengthen the affiliation between the two societies. BASO members did get affiliate membership to ESSO, however, with the updated agreement, BASO members now enjoy standard membership benefits of ESSO including reduced registration rates to the ESSO Annual conference, courses and training programmes. BASO members also get the opportunity to apply to an international career development programme and access to the membership restricted areas to the ESSO website. BASO individuals will now have the voting right at the ESSO General Assembly.

NIHR’s Clinical Research Network

The Association also maintains its relationship with the NIHR’s Clinical Research Network, and supports the ‘Tomorrow’s Leaders’ programme which enrols the future leaders in the field of surgical oncology and research. These leaders are encouraged to join our trainees' membership and are offered support to enhance their career in surgical oncology via short workshops, methodology training, research grant, etc.

National Clinical Guidelines

BASO continues to maintain a strong presence when National Clinical Guidelines are either developed or updated. BASO Trustees are appointed as the Specialist Advisors for the NICE’s Interventional Procedure Programmes. Furthermore, BASO Trustees have been contributing to numerous consultations, and are active members of the different Cancer Commissioning Groups.

BASO@ UK Oncology Forum

BASO maintains an ongoing collaboration with the UK Oncology Forum and delivers a pan-tumour session every year. This national clinically focussed meeting is open to UK Cancer HCPs. And is free for BASO members to attend. In 2020, BASO hosted the 'BASO updates on multidisciplinary teams ' session chaired by Mr Hamady, BASO Vice President. BASO Council aims to develop this collaboration further.

-5-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

BASO Symposium @ Association of Surgeons of India Annual Conference

BASO delivered a joint BASO-ASI Symposium on ‘ Extremity Soft Tissue Sarcoma – A Therapeutic Quagmire’ at the ASI 80[th] Annual conference in December 2020. The conference was a well-received meeting with 6000 delegates in attendance. The session was co-chaired by Mr Anant Desai, BASO Trustee and ASI Panelists, and BASO talks were presented by Mr Andrew Hayes, Consultant Sarcoma Surgeon, and Mr Michael Parry, Orthopaedic Oncologists.

BASO Council is keen on developing further collaborative sessions at their future meetings

Cancer Services Committee

BASO~ACS continues chairing the RCSENG’s Cancer Services Committee , and is now invited to offer expert advice towards the ‘Future of Surgery’ Commission, and has contributed on ‘Restructuring of the MDTs’, and GMC’s proposal on Draft Credentialing Frame Work. As a surgical oncology society, we are actively engaged in decision making with organisations such as NICE, NCEPOD, Specialist Cancer CRG, the Royal College of Surgeons, and GMC.

BASO Publications

In addition, this accounting year, BASO also engaged with and contributed to:

BASO Endorsed Meetings

This year, BASO endorsed the following events & meetings:

BASO~ACS continues to support and promote the development of cancer treatment, research, patient care, and education and training of our future generation of oncologists.

Financial Review

Membership

Membership of the Association remains stable during the course of the year. Membership subscriptions for 2020-21 continued to be kept intentionally low at £180 for full membership as the Association still holds high levels of reserves.

The subscriptions for the BASO Trainees for 2020-21 is also unchanged. As agreed at the 2017 AGM, BASO offers a 50% discounted fee to the Full Membership of the BASO~ACS for two years to a BASO Trainees member upon completion of training, provided they were the paying member of the Society for two consecutive years.

-6-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued) YEAR ENDED 30 JUNE 2021

EJSO

The profits from the EJSO are offset against the cost of the membership subscriptions to the EJSO and these are included in the final reconciliation. A new Journal Publishing agreement between ESSO and BASO as owners, and Elsevier as publishers of the Journal, was made as of 9[th] December 2020. Elsevier paid a oneoff signing bonus of £50,000 to both the Societies that was split 50:50 between BASO and ESSO.

This new agreement with added benefits and revenues for both the Societies began on 1[st] January 2021 and shall conclude on 31[st] December 2027. All the parties agreed to meet between Sep-Dec 2024 to review the performance of the Journal in light of expectations and overall market conditions. The updated agreement and the EJSO progression will secure the future income stream for BASO.

The Journal has generated a healthy profit for BASO~ACS in 2020 with an income of £65,367 after the deduction of BASO’s membership subscription for the year. It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio.

BASO Grants and Prizes

BASO (NIHR) Research Project Grant The 2020 BASO NIHR Research Project Grant of £3,000 was awarded to the CovidSurg- Cancer Study in April 2020. Two further applications were received in response to the 2020 call for submissions. It was agreed by the NC to merge these applications with the 2021 round of submissions, thereby, allowing trainees to submit their research work for BASO (NIHR) research grant.

Ronald Raven Travelling Fellowship Grant of £3,000 in total was awarded to: Mr Neil Foden , SPR, Otolaryngology, South London Deanery Laurence Glancz, ST8 Neurosurgery Trainee, Nottingham University Hospitals NHS Trust BASO Trainees Prize were awarded at the following external meetings: SCTS Annual Scientific Meeting ASiT Annual Conference

BASO Annual Meeting 2020

BASO Trustees strongly feel that the Charity’s continues fulfilling its objective by promoting and sponsoring advancement in research and education of surgical oncology through another successful meeting. The meeting was supported by industry sponsorship and had relatively lower costs. Also, to add to members' benefits, the BASO Council decided to offer the meeting FREE to BASO members. Overall the meeting generated a small profit.

The conference raised the Association’s presence in the field of Cancer research and has helped engage with various organisations and groups; and offered a great networking platform for the BASO members; recruiting new members. The Association maintains a strong level of reserves and has acquired a new income stream with the EJSO; we can continue to invest our reserves in the promotion of education, training and research via our Annual Conferences. However, we do hope to move towards a cost-neutral financial structure.

Structure, Governance and Management

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067).

-7-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699).

The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work co-operatively together.

In May 2020 both the Associations separated their joint database and IT services, and agreed to retain historic records of joint members or those members of ABS who have attended BASO events and vice-versa. The service agreement is subject to periodic review to ensure its continuing relevance and fairness to both Associations. No further substantive changes are envisaged at this stage.

The Ordinary Members of the BASO~ACS National Committee (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a ‘Call for Nominations’. Officer posts are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM. BASO~ACS has National Committee meetings four times a year.

BASO also administer the Royal College of Surgeons of England’s Cancer Services Committee, which meets three times a year and is chaired by the President of BASO~ACS. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year.

The Trustees pay due regard to the Charity Commission’s guidance on public benefit when deciding what activities the Charity should undertake.

Reserves Policy

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. The level of reserves, and income from conferences and subscriptions, is crucial to the Association’s work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association’s reserves.

-8-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

TRUSTEES' ANNUAL REPORT (continued)

YEAR ENDED 30 JUNE 2021

Plans for the Future

Growth of the core membership and the breadth of specialisms represented were set out as key aims for 202021. Whilst overall growth has not materialised, membership numbers have remained steady and the Trustees are actively seeking stronger links with other Associations, many of whom have been invited to nominate observers to Council meetings and to whose meetings we have offered to send observers, with the intention of improving communication and understanding in areas of common interest. Several of these Associations have expressed an interest and the Trustees look forward to reporting on progress in this area in future. The present Trustees themselves represent a broad cross-section of specialisms and so bring a welcome breadth of experience and perspective to the steering process.

BASO Trustees intend to establish affiliation support for smaller complex cancer surgical groups, offering them affiliation to BASO membership and endorsement of their meeting, etc., thereby expanding the Association’s distinctive “brand” as the umbrella Society for all Cancer Surgeons.

To this end, in 2010-21 the Association has made significant contribution to different consultations as organised by NICE. The Trustees are actively developing collaborations with different Royal Colleges, Cancer Commissioning Boards/Reference Groups, Public Health England, GMC and many other interested parties with the aim – as always - of sharing knowledge, opening out debate and improving best practice for the benefit of cancer patients.

The Cancer Services Committee is currently reviewing the issue of ‘complex surgical oncology training’, ‘Fellowship training recommendations for cancer surgery ‘and ‘MDT revisions & review’. BASO has been invited to contribute to the ‘future of surgery’ commissioning of the RCS; and the CSC would ideally aspire to have direct representation on the RCS Council. The Cancer Services Committee has also been invited to be involved in setting the quality metrics for cancer surgery for the UK, in conjunction with CRUK and NCIN. Mr Hassan Malik, President is representing BASO on this Committee.

BASO Trustees have joined the Specialised Cancer Clinical Commissioning Group and using its wealth of experts are supporting service development in cancer surgery. BASO will continue to fund several small grants to support surgical oncology research in partnership with the NIHR. This initiative will foster increasing the breadth of surgical research as well as increasing recruitment of patients into NIHR portfolio studies.

BASO will broaden its grants and support to regional level meetings, and Student Surgical Societies. BASO Trainees membership is now open to Medical Students and Foundation Year Trainees, those interested in surgical oncology, with the aim to support their training and further education & career in cancer surgery.

As training and work pressures change with an ever-evolving healthcare service, our BASO Trainees group intends to improve the experience, training, and professional competence of surgical trainees with an interest in oncology, principally in academic and research matters.

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 21 November 2021 and signed on their behalf by:

Mr John Whiting Honorary Treasurer

-9-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

YEAR ENDED 30 JUNE 2021

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2021 which are set out on pages 11 to 18.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

  1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

C A Barker FCA

Edmund Carr LLP 146 New London Road Chelmsford CM2 0AW

7 December 2021

-10-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)

YEAR ENDED 30 JUNE 2021

Note
£
£
INCOME from:
Charitable activities:
Members' subscriptions
32,836
-
Scientific conference
2
4,110
-
Publications - EJSO
101,547
-
Other trading activities
47
-
Investments
3
195
4
TOTAL INCOME
138,735
4
EXPENDITURE on:
Charitable activities
Subscriptions - ESSO
7,366
-
Scientific conference
2
3,188
-
Publications - EJSO
11,180
-
Fellowships & awards
4
500
4,000
National Committee and support costs
5
53,331
-
TOTAL EXPENDITURE
75,565
4,000
NET INCOME/(EXPENDITURE)
63,170
(3,996)
Transfers between funds
(2,500)
2,500
NET MOVEMENT IN FUNDS
60,670
(1,496)
RECONCILIATION OF FUNDS
Total funds brought forward
194,062
34,951
Total funds carried forward
254,732
33,455
Unrestricted
Funds
Funds
Restricted		 Note
£
£
INCOME from:
Charitable activities:
Members' subscriptions
32,836
-
Scientific conference
2
4,110
-
Publications - EJSO
101,547
-
Other trading activities
47
-
Investments
3
195
4
TOTAL INCOME
138,735
4
EXPENDITURE on:
Charitable activities
Subscriptions - ESSO
7,366
-
Scientific conference
2
3,188
-
Publications - EJSO
11,180
-
Fellowships & awards
4
500
4,000
National Committee and support costs
5
53,331
-
TOTAL EXPENDITURE
75,565
4,000
NET INCOME/(EXPENDITURE)
63,170
(3,996)
Transfers between funds
(2,500)
2,500
NET MOVEMENT IN FUNDS
60,670
(1,496)
RECONCILIATION OF FUNDS
Total funds brought forward
194,062
34,951
Total funds carried forward
254,732
33,455
Unrestricted
Funds
Funds
Restricted		 Total Funds
2021
£
32,836
4,110
101,547
47
199		 Total Funds
2020
£
33,922
26,945
60,234
400
947
4 138,739 122,448
-
-
-
4,000
-		 7,366
3,188
11,180
4,500
53,331		 6,445
53,308
11,701
14,010
79,990
4,000 79,565 165,454
(3,996)
2,500
(1,496)
34,951		 59,174
-
-
229,013		 (43,006)
-
(43,006)
272,019
33,455 288,187 229,013

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 13 to 18 form part of these financial statements.

-11-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

BALANCE SHEET AS AT 30 JUNE 2021

Note
FIXED ASSETS
Tangible assets
10
CURRENT ASSETS
Debtors
11
Cash at bank
CREDITORS: Amounts falling due
within one year
12
NET CURRENT ASSETS
TOTAL ASSETS LESS CURRENT LIABILITIES
NET ASSETS
FUNDS
Unrestricted
13
Restricted
14
TOTAL FUNDS		 £
£
704
11,188
340,605
351,793
(64,310)
287,483
288,187
288,187
254,732
33,455
288,187
2021		 £
£
494
5,157
265,367
270,524
(42,005)
228,519
229,013
229,013
194,062
34,951
229,013
2020		 £
£
494
5,157
265,367
270,524
(42,005)
228,519
229,013
229,013
194,062
34,951
229,013
2020
229,013
229,013
194,062
34,951
229,013

For the year ending 30 June 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on 21 November 2021 and are signed on their behalf by:

MR HASSAN MALIK

MR JOHN WHITING

Company Registration Number: 7225131

The notes on pages 13 to 18 form part of these financial statements.

-12-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The Trustees have considered the impact of the Covid-19 pandemic in their assessment of the charity’s ability to prepare accounts as a going concern. It is difficult to predict the impact on the charity and its funders, but having taken all the factors into account, the Trustees are of the opinion that the charity has sufficient resources to continue trading for the next 12 months from the date of signing these accounts.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity. Staff and office costs are recharged to the charity under the service agreement with ABS.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment 25% reducing balance Fixtures & fittings 25% reducing balance

-13-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Designated funds – these are funds set aside by the trustees out of unrestricted funds for specific future purposes or projects.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

2. CHARITABLE ACTIVITIES SCIENTIFIC CONFERENCE

Income
Fees
Lecture grants
Expenditure
Speaker expenses
Venue and catering costs
Other conference costs		 Unrestricted
Funds
£
4,110
-
4,110
-
-
3,188
3,188		 Restricted
Funds
£
-
-
-
-
-
-
-		 Total Funds
2021
£
4,110
-
4,110
-
-
3,188
3,188		 Total Funds
2020
£
25,945
1,000
26,945
6,172
32,022
15,114
53,308

All conference income and expenditure in 2020 was unrestricted.

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

Ronald Raven Prize
Ronald Raven Travel Scholarships
Alan Edwards Memorial Fund
Other Awards		 Unrestricted
Funds
£
-
-
-
500
500		 Restricted
Funds
£
600
3,000
400
-
4,000		 Total Funds
2021
£
600
3,000
400
500
4,500		 Total Funds
2020
£
600
3,000
400
10,010
14,010

In 2020 Other Awards were paid from unrestricted funds. All other prizes were paid from restricted funds.

-14-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

5. NATIONAL COMMITTEE & SUPPORT COSTS

Staff salaries and pension costs
SOTA committee & meeting costs
Other support costs
Governance costs (note 6)
National committee costs
Service agreement charges		 Unrestricted
Funds
£
40,272
-
1,800
-
5,344
5,915
53,331		 Restricted
Funds
£
-
-
-
-
-
-
-		 Total Funds
2021
£
40,272
-
1,800
-
5,344
5,915
53,331		 Total Funds
2020
£
41,501
9,207
11,248
1,731
7,436
8,867
79,990

All national committee and support costs in 2020 were unrestricted.

6. GOVERNANCE COSTS

Accounting and payroll services
Independent examination fee
Fees payable to independent examiner
Bank charges
Other professional fees
7. STAFF COSTS AND EMOLUMENTS		 Unrestricted
Funds
£
4,025
575
4,600
416
899
5,915		 Restricted
Funds
£
-
-
-
-
-
-		 Total Funds
2021
£
4,025
575
4,600
416
899
5,915		 Total Funds
2020
£
3,871
575
4,446
438
3,983
8,867
Total staff costs were as follows:
Wages & salaries
Pension costs (defined contribution scheme)		 2021
£
37,072
3,200
40,272		 2020
£
38,301
3,200
41,501

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8) (2020 - 1 employee and 0.8 FTE)

No employee received remuneration of more than £60,000 during the period.

-15-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

8. NET OUTGOING RESOURCES FOR THE YEAR

2021 2020
This is stated after charging: £ £
Depreciation 168 167

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period. Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company. Expenses totalling £188 were reimbursed to 1 trustee during the period (2020 - £4,015 to 9 Trustees).

10. TANGIBLE FIXED ASSETS

COST
At 1 July 2020
Additions
Disposals
At 30 June 2021
DEPRECIATION
At 1 July 2020
Charge for the year
At 30 June 2021
NET BOOK VALUE
At 30 June 2021
At 30 June 2020
11. DEBTORS
Prepayments
Other Debtors		 Computer
equipment
£
2,682
378
-
3,060
2,221
154		 Fixtures
& fittings
£
2,421
-
-
2,421
2,388
14		 Total
£
5,103
378
-
5,481
4,609
168
2,375 2,402 4,777
685
461		 19
33
2021
£
1,162
10,026
11,188		 704
494
2020
£
-
5,157
5,157

-16-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2021

12. CREDITORS: Amounts falling due within one year

Trade creditors
Other creditors
Accruals
Deferred income		 2021
£
-
-
8,985
55,325
64,310		 2020
£
1,674
125
5,791
34,415
42,005

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

13. UNRESTRICTED FUNDS
Current year
Balance at
01/07/2020
£
General unrestricted funds
194,062
Prior year
Balance at
01/07/2019
£
General unrestricted funds
233,138
14. RESTRICTED FUNDS
Current year
Balance at
01/07/2020
£
a)
Alan Edwards Memorial Fund
5,968
b)
Ronald Raven Prize Fund
569
c)
Ronald Raven Travelling
28,414
Fellowship Fund
34,951		 Balance at
01/07/2020
£
194,062		 Incoming
Outgoing
£
£
138,735
(75,565)
Incoming
Outgoing
£
£
122,378
(161,454)
Incoming
Outgoing
£
£
1
(400)
-
(600)
3
(3,000)
4
(4,000)
Movement in resou
Movement in resou		 Transfers
£
(2,500)
Transfers
£
-
Transfers
£
-
2,500
-
2,500
rces:
rces:		 Balance at
30/06/2021
£
254,732
Balance at
01/07/2019
£
233,138		 Balance at
30/06/2020
£
194,062
Balance at
30/06/2021
£
5,569
2,469
25,417
34,951 33,455

-17-

BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2021

14. RESTRICTED FUNDS

Prior year
a)
Alan Edwards Memorial Fund
b)
Ronald Raven Prize Fund
c)
Ronald Raven Travelling
Fellowship Fund		 Balance at
01/07/2019
£
6,357
1,163
31,361
38,881		 Movement in resources:
Incoming
Outgoing
£
£
11
(400)
6
(600)
53
(3,000)
70
(4,000)		 Movement in resources:
Incoming
Outgoing
£
£
11
(400)
6
(600)
53
(3,000)
70
(4,000)		 Transfers
£
-
-
-
-		 Balance at
30/06/2020
£
5,968
569
28,414
70 (4,000) 34,951

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

Current year
Restricted funds
Unrestricted funds
Prior year
Restricted funds
Unrestricted funds		 Tangible
fixed assets
£
-
704		 Other net
assets
£
33,455
254,028
287,483
Other net
assets
£
34,951
193,568
228,519		 Total
£
33,455
254,732
704 288,187
Tangible
fixed assets
£
-
494		 Total
£
34,951
194,062
494 229,013

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.

-18-